Classical Markers Like ER and Ki-67, but Also Survivin and Perk, Could Be Involved in the Pathological Response to Gemcitabine, Adriamycin and Paclitaxel (GAT) in Locally Advanced Breast Cancer Patients: Results from the GEICAM/2002-01 Phase II Study